Research programme: hepatitis B vaccine - GeoVax Labs

Drug Profile

Research programme: hepatitis B vaccine - GeoVax Labs

Latest Information Update: 13 Apr 2017

Price : $50

At a glance

  • Originator GeoVax Labs
  • Developer Georgia State University; Peking University Shenzhen Graduate School
  • Class Hepatitis B vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Hepatitis B

Most Recent Events

  • 27 Mar 2017 Preclinical trials in Hepatitis B in USA (Parenteral)
  • 17 Jan 2017 GeoVax and Georgia State University agree to develop hepatitis B vaccine for Hepatitis B virus infections
  • 06 Jun 2016 Early research in Hepatitis B treatment in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top